VBIZF (Viva Biotech Holdings) Interest Expense : $-7.4 Mil (TTM As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Viva Biotech Holdings's interest expense for the six months ended in Jun. 2024 was $ -4.3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $-7.4 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Viva Biotech Holdings's Operating Income for the six months ended in Jun. 2024 was $ 19.3 Mil. Viva Biotech Holdings's Interest Expense for the six months ended in Jun. 2024 was $ -4.3 Mil. Viva Biotech Holdings's Interest Coverage for the quarter that ended in Jun. 2024 was 4.48. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Viva Biotech Holdings Interest Expense Historical Data

The historical data trend for Viva Biotech Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Interest Expense Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-9.50

-28.75

-26.49

-24.73

-7.40

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Interest Expense	Get a 7-Day Free Trial											-13.71	-12.29	-12.41	-4.32	-3.10

Viva Biotech Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-7.4 Mil.

Viva Biotech Holdings (OTCPK:VBIZF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Viva Biotech Holdings's Interest Expense for the six months ended in Jun. 2024 was $-4.3 Mil. Its Operating Income for the six months ended in Jun. 2024 was $19.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was $122.4 Mil.

Viva Biotech Holdings's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2024 )	/	Interest Expense (Q: Jun. 2024 )
	=	-1	*	19.34	/	-4.321
	=	4.48

The higher the ratio, the stronger the company's financial strength is.

Viva Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (OTCPK:VBIZF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

01873:Hong Kong VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.